VivoSeq
Other

Airway Obstruction

39

Pipeline Programs↗

2

Active Trials↗

15

Companies Involved↗

Airway obstruction is a moderately active landscape with 39 programs across 15 companies. The most active players are Eli Lilly, Roche, Viatris. 16 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

28/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Roche logo

Roche

3 programs

Phase 2Viatris logo

Viatris

1 program

ApprovedA

Azurity Pharmaceuticals

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedSanofi logo

Sanofi

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

33 of 40 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody615%Radiopharmaceutical13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 100% of 40 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed8 · 57%
Unknown status4 · 29%
Not yet recruiting1 · 7%
Recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
Recruiting·RRoswell Park Cancer Institute·Phase 1/2·NCT06306638·53 enrolled
Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
Not yet recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06604351·39 enrolled
Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Completed·IIndiana University School of Medicine·N/A·NCT00435994·59 enrolled
A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)
Completed·Roche logoRoche·Phase 2·NCT01196039·29 enrolled
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
Completed·Roche logoRoche·Phase 2·NCT00434434·61 enrolled
A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Completed·Roche logoRoche·Phase 2·NCT00983658·29 enrolled
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
Completed·MMercator MedSystems, Inc.·N/A·NCT02066103·20 enrolled
Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients
Completed·SSt. Joseph's Healthcare Hamilton·Phase 3·NCT05456542·100 enrolled
A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Completed·Roche logoRoche·Phase 2·NCT00781443·29 enrolled
Heliox in Experimental Upper Airway Obstruction
Completed·UUniversity of Witten/Herdecke·Phase 1/2·NCT00788788·44 enrolled
A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction
Unknown status·ZZhongda Hospital·Phase 2·NCT02565927·60 enrolled
Comparison of High Dose and Low Dose Dexamethasone in Preventing Post-Extubation Airway Obstruction in Adults
Unknown status·MMackay Memorial Hospital·Phase 2·NCT00548483·80 enrolled
Dexamethasone and the Prevention of Post-Extubation Airway Obstruction in Adults
Unknown status·MMackay Memorial Hospital·Phase 2·NCT00452062·70 enrolled
Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)
Unknown status·HHat Yai Medical Education Center·N/A·NCT05550402·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)